The Catalan Institute of Oncology (ICO) is offering a postdoctoral position in Translational Cancer Research, specifically within the Resistance, Chemotherapy and Predictive Biomarkers (RCPB) group led by Dr Eva Martínez Balibrea. The position is based at the Can Ruti Campus (IGTP/ICO) in the Barcelona area, Spain. The group focuses on understanding mechanisms of resistance to cancer therapies, primarily in colorectal cancer, and aims to identify predictive biomarkers to improve personalized treatment strategies and discover novel drug targets and therapeutic approaches.

The research environment is highly translational and clinically integrated, with close collaboration with the Medical Oncology Department of ICO-Badalona. The group is involved in major institutional programs such as ProCURE (ICO) and CARE (IGTP), and participates in international collaborations including the EORTC Pathobiology Group and the COST Action IMMUNO-model. Research topics include deciphering mechanisms of chemotherapy resistance, identifying and validating biomarkers, studying genetic and epigenetic factors, and developing in vitro and ex vivo models to test new therapeutic strategies. The group employs advanced techniques such as omics, 3D cultures, and in vivo models, and is engaged in projects funded by European and national agencies.

Applicants should have a PhD in cancer biology, be in the early postdoctoral stage, and demonstrate strong independence, leadership, and teamwork skills. C1 level English and international mobility are required, along with at least two first-author Q1 publications. Experience with in vivo models, 3D cultures, omics data, and immunology is highly valued. The position offers a permanent contract with a salary equivalent to a Sara Borrell contract. The start date is expected in Q2 2026.

To apply, candidates should use the provided application link and ensure all requirements are met. For further information, Dr Eva Martínez Balibrea can be contacted at [email protected]. The deadline for applications is April 1, 2026.

Keywords: colorectal cancer, cancer biology, biomarkers, chemotherapy resistance, immunotherapy, predictive biomarkers, translational research, drug resistance, omics, in vivo models.